Zydus Lifesciences Q3 Results: Profit Expectations Ko Tod Diya, Share **4%** Bhaga!

OTHER
Whalesbook Logo
AuthorAarav Shah|Published at:
Zydus Lifesciences Q3 Results: Profit Expectations Ko Tod Diya, Share **4%** Bhaga!
Overview

Bhaiyo aur Behno, Zydus Lifesciences ne apna Q3 ka result announce kiya hai aur numbers ne sabko chaunka diya! Company ne expectations se zyada profit aur revenue report kiya hai, jiske baad stock mein **4%** se zyada ki tezi dekhne ko mili.

Q3 Mein Zydus Ne Dhamaal Macha Diya!

Chalo, pehle numbers ki baat karte hain. Zydus Lifesciences ne is quarter mein ₹1,042 Crore ka net profit kamaya hai, jo ki analysts ke ₹940 Crore ke estimate se kaafi upar hai. Pichhle saal ke muqable yeh 2% zyada hai. Asal dhamaka toh revenue growth mein dikha, jo 30.3% badh kar ₹6,865 Crore ho gaya, pichhle saal ke ₹5,269 Crore ke comparison mein. Market ke ₹6,294.3 Crore ke estimate ko bhi company ne cross kar diya. EBITDA bhi 31% jump karke ₹1,817 Crore pahunch gaya, jo ₹1,516 Crore ke estimate se kaafi zyada hai. Company ka profit margin bhi 26.5% par pahunch gaya, jo pichhle saal ke 26.3% se thoda behtar aur analysts ke 24% ke estimate se kaafi upar hai. Ye sab numbers dekh kar hi toh stock February 9th ko ₹933.35 ke intraday high tak pahunch gaya tha.

Valuation Kaisa Lag Raha Hai?

Ab baat karte hain Zydus Lifesciences ke valuation ki. Current prices par company ka P/E ratio lagbhag 17.3x se 17.96x ke aas paas chal raha hai. Agar isko bade players se compare karein toh Sun Pharmaceutical Industries ka P/E 34.4x se 36.96x hai, aur Cipla ka 22.61x se 23.65x. Dr. Reddy's Laboratories ka valuation Zydus ke lagbhag same hi hai, 17.1x se 18.18x. Indian pharma sector ka average P/E 29.4x hai. Toh iss hisaab se Zydus ka valuation kaafi attractive lag raha hai, matlab growth ke comparison mein stock abhi bhi sasta lag raha hai.

Sector Ka Outlook Aur Kuch Chintaayein

Indian pharma sector mein FY26 mein 7-9% ki moderate growth ka andaza hai, jismein domestic aur Europe markets ka yogdaan rahega. Lekin US market mein growth thoda slow ho kar 3-5% rehne ki ummeed hai. Government support aur domestic demand acchi hai, par quality scrutiny aur supply chain issues jaise challenges bhi hain.

Ek chinta yeh hai ki agar sequential numbers dekhein toh Q2 FY26 mein revenue 6.9% kam hua tha. US market, jo Zydus ka sabse bada contributor hai, wahan growth kam hone ki ummeed hai. Competitors bhi pressure mein hain; jaise Cipla ne recently profit mein badi girawat dikhai hai. Ye sab factors future mein company ke performance ko affect kar sakte hain.

Analysts Kya Bol Rahe Hain?

Phir bhi, analysts ka Zydus par bharosa bana hua hai. Unka average price target ₹1040.50 hai, jo current levels se 17% se zyada ka upside dikha raha hai. Company international acquisitions aur innovation par focus kar rahi hai, jo long-term growth ke liye accha sign hai. Agle hafte February 10, 2026 ko hone wali earnings call par management se aur clarity milegi.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.